Key result
HIT triggers thrombosis via PF4 antibodies, requiring non-heparin anticoagulation like DTIs or anti-Xa agents.
Answers are grounded in this paper and cite their sources.
BACKGROUND: Heparin is widely used for the prophylaxis of venous thrombo-embolism and pulmonary embolism. Thrombocytopaenia and the sequale of thrombosis are uncommon adverse effects of therapy which are associated with high morbidity and mortality. OBJECTIVE: To review the clinical-pathologic features of heparin induced thrombocytopaenia/thrombosis. DATA SOURCES: Reputable haematology journals and the internet in English. Searches included thrombosis, heparin, and heparin induced thrombocytopaenia. DATA SELECTION: Only relevant journals and internet sources were selected for this review. In particular leading journals in thrombosis and anticoagulants. DATA EXTRACTION: High quality abstracts, papers and internet articles were the main source of information. DATA SYNTHESIS: Information from the selected abstracts and papers was used'for the paper. CONCLUSION: The clinical effects of heparin induced thrombocytopaenia/thrombosis (HIT/T) include venous and arterial events the latter of which include limb ischaemia, myocardial infarction and stroke. The pathogenesis of this complication is related the formation of heparin-platelet factor 4 antibodies which can be demonstrated in the laboratory by functional and immunoassays. Management requires alternative anticoagulation with agents that have no cross reactivity with heparin platelet factor 4 antibodies. These agents include danapranoid, direct thrombin inhibitors and newer agents like fondaparinux and rivaroxaban with anti Xa activity.
No takes yet. Share an insight, caveat, or question.
PA Dave (2010) conducted a review in Heparin-induced thrombocytopenia/thrombosis (HIT/T). Heparin and alternative anticoagulants (danaparoid, direct thrombin inhibitors, fondaparinux, rivaroxaban) was evaluated. Heparin-induced thrombocytopenia/thrombosis is driven by heparin-PF4 antibodies causing venous and arterial thrombosis, requiring alternative anticoagulation such as DTIs or anti-Xa agents.
Synapse has enriched 10 related papers. Consider them for comparative context: